

Company Overview

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition

Sep 17 2021, 7:30 AM EDT

Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results

Aug 11 2021, 4:01 PM EDT

Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update

Aug 4 2021, 7:30 AM EDT

Stock Overview

Symbol	NAVB
Exchange	NYSE American
Market Cap	
Last Price	\$
52-Week	\$ - \$

Investor Relations

Jed A. Latkin
Chief Executive Officer, Chief
Operating Officer and Chief
Financial Officer
T: 614-973-7490
jlatkin@navidea.com

Management Team

Jed A. Latkin

Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

William Regan

Chief Compliance Officer

Michael Rosol, Ph.D.

Chief Medical Officer

Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue
Suite 240
Dublin, OH 43017

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.